Troponin I (cTnI) is a unique protein of cardiomyocytes, which can significantly regulate the contraction of cardiomyocytes. It is widely used in the clinical detection of myocardial injury and unstable angina pectoris. After the onset of such patients, cTnI appears early, lasts for a long time, has the advantages of myocardial specificity and long diagnostic window period, and is the preferred marker for the diagnosis of myocardial infarction
Detection range | sample size | Sample type | Test time |
0.1~50ng/mL | 60μl | Whole blood / serum / plasma | 15min |
See a doctor | Chest pain/chest tightness | |||
Medical history and physical examination | Suspected ACS (Acute Coronary Syndrome) | |||
electrocardiogram | Persistent ST segment elevation | Abnormal St/T segment ↓ | ![]() | ECG normal ↓ |
Biochemical test | ↓Confirm | CTN was positive | Troponin CTN negative ×2 | |
Risk stratification | high-risk | Low risk | ||
diagnosis | ST-segment elevation myocardial infarction STEMI | Non-ST-segment elevation myocardial infarction NSTEMI | Unstable angina pectoris UA | |
treatment | Reperfusion | Interventional therapy | Non-interventional therapy |
cTnT <0.1 μg/L is normal;> 0.2 μg/L is the diagnostic cut-off value;> 0.5 μg/L can be diagnosed as acute myocardial infarction; cTnI <0.2 μg/L is normal;> 1.5 μg/L is the diagnostic cut-off value ( Using ELISA method)
Cardiology, emergency, laboratory, pediatrics, hematology, oncology, Nephrology, surgery, etc
Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise engaged in the research and development, production and operation of in vitro diagnostic products. The in vitro diagnostic products developed by the company cover POCT series, microbial series, biochemical series and immune series reagents and supporting instruments.
The company has always adhered to the core concept of "fast and accurate, living up to life", committed to providing society with excellent products and services, and contributing to the cause of human health.